1,272,714 Shares in OrthoPediatrics Corp. $KIDS Bought by BlackRock Inc.

BlackRock Inc. acquired a new stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,272,714 shares of the company’s stock, valued at approximately $24,347,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after acquiring an additional 645 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,235 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after purchasing an additional 2,561 shares in the last quarter. Finally, Barclays PLC increased its position in shares of OrthoPediatrics by 10.7% in the fourth quarter. Barclays PLC now owns 26,405 shares of the company’s stock worth $469,000 after purchasing an additional 2,561 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC raised their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. BTIG Research boosted their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Piper Sandler reissued an “overweight” rating and issued a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Finally, Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $26.44.

Insider Activity

In other news, major shareholder Squadron Capital Llc sold 10,131 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.10, for a total value of $234,026.10. Following the completion of the sale, the insider owned 6,526,633 shares of the company’s stock, valued at approximately $150,765,222.30. This represents a 0.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David R. Pelizzon sold 10,131 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.10, for a total transaction of $234,026.10. Following the transaction, the director directly owned 6,526,633 shares in the company, valued at approximately $150,765,222.30. This represents a 0.15% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 1,125,393 shares of company stock valued at $26,113,488. Corporate insiders own 32.50% of the company’s stock.

Key Headlines Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Wall Street’s consensus rating remains Moderate Buy, with an average price target of $26.44. Piper Sandler maintained an Overweight rating and raised its target to $25, while Needham increased its target to $35 and reiterated Buy. OrthoPediatrics analyst coverage
• Positive Sentiment: Several institutions increased their positions during the first half of the year. Millennium Management raised its stake by 55.3%, Goldman Sachs more than doubled its holdings, and institutional investors collectively own approximately 69.05% of outstanding shares.
• Positive Sentiment: OrthoPediatrics recently exceeded quarterly expectations, reporting revenue of $70.51 million versus the $68.21 million consensus estimate and a loss of $0.26 per share, better than the expected $0.30 loss. This suggests operating results are progressing ahead of forecasts, despite the company remaining unprofitable.
• Neutral Sentiment: The reported transactions appear in multiple director, major-shareholder and beneficial-ownership filings, so some disclosures may represent overlapping ownership records rather than separate sales. The reporting holders still controlled roughly 6.53 million shares after the transactions. SEC ownership filing
• Negative Sentiment: Director David Pelizzon and major shareholder Jennifer N. Pritzker reported sales totaling 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. The sales reduced reported ownership by 4.76% and may weigh on sentiment by creating an insider-selling overhang.
• Negative Sentiment: The same ownership group also reported sales of 10,131 shares on September 1 at $23.10, valued at about $234,000 per filing. While the 0.15% reduction is modest, the additional selling reinforces the near-term supply concern. OrthoPediatrics insider sale report

OrthoPediatrics Stock Performance

Shares of NASDAQ KIDS opened at $22.80 on Thursday. The stock has a market cap of $595.31 million, a price-to-earnings ratio of -13.57 and a beta of 0.99. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74. The stock’s 50-day moving average is $21.68 and its 200 day moving average is $18.80.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. On average, sell-side analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.